Cantor Fitzgerald Forecasts Stronger Earnings for Arvinas

Arvinas, Inc. (NASDAQ:ARVN) – Analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for Arvinas in a research report issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($2.71) for the year, up from their prior estimate of ($6.11). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.81) per share.

A number of other equities analysts have also commented on ARVN. The Goldman Sachs Group lowered Arvinas from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $70.00 to $15.00 in a research note on Thursday, March 13th. Guggenheim lowered their target price on Arvinas from $57.00 to $32.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. Bank of America dropped their target price on Arvinas from $54.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, March 12th. Wells Fargo & Company set a $26.00 target price on Arvinas and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. Finally, Wedbush lowered shares of Arvinas from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $57.00 to $12.00 in a research note on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.47.

Arvinas Stock Up 3.4 %

Shares of NASDAQ:ARVN opened at $9.00 on Thursday. Arvinas has a 12-month low of $7.91 and a 12-month high of $44.85. The company’s 50 day moving average price is $16.44 and its two-hundred day moving average price is $21.41. The firm has a market cap of $618.95 million, a PE ratio of -3.25 and a beta of 1.95.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the firm earned ($2.53) earnings per share.

Insider Transactions at Arvinas

In related news, CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the transaction, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the sale, the insider now directly owns 110,023 shares of the company’s stock, valued at $945,097.57. This represents a 7.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,230 shares of company stock valued at $769,402 over the last ninety days. 5.23% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in Arvinas during the 4th quarter valued at $28,000. KBC Group NV raised its holdings in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after purchasing an additional 1,255 shares during the last quarter. Quantbot Technologies LP boosted its holdings in Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after purchasing an additional 2,601 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Arvinas in the 4th quarter worth about $171,000. Finally, Tema Etfs LLC purchased a new stake in Arvinas in the 4th quarter valued at about $227,000. Institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.